Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 11/20 | 0.44 |
| ▸ | CTSS | P25774 | 7/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 2/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2441956 | 1.00 | CTSK (0.44) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL937622 | 1.00 | CTSK (0.44) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL27133818 | 0.92 | CTSK (0.46) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL16387553 | 0.92 | CTSK (0.46) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL13422140 | 0.92 | CTSK (0.46) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL31240143 | 0.89 | CTSK (0.48) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL16546620 | 0.89 | CTSK (0.48) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL2063018 | 0.87 | CYP1A2 (0.58) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL2063020 | 0.87 | CYP1A2 (0.58) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL24073146 | 0.86 | CYP1A2 (0.46) | CTSKCTSSCYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3511328-B1 | MONOBACTAM ORGANIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | NOVARTIS AG (CH) | 2021-03-03 | — | — | EP | disclosed |
| US-20200276169-A1 | MONOBACTAM ORGANIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2020-09-03 | — | — | US | disclosed |
| US-10369138-B2 | Monobactam organic compounds for the treatment of bacterial infections | NOVARTIS AG (CH) | 2019-08-06 | — | — | US | disclosed |
| US-20190231752-A1 | MONOBACTAM ORGANIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2019-08-01 | — | — | US | disclosed |
| EP-3511328-A1 | MONOBACTAM ORGANIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | Novartis AG (CH) | 2019-07-17 | — | — | EP | disclosed |
| US-20160051523-A1 | MONOBACTAM ORGANIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | NOVARTIS AG (CH) | 2016-02-25 | — | — | US | disclosed |
| US-9174978-B2 | Monobactam organic compounds for the treatment of bacterial infections | NOVARTIS AG (CH) | 2015-11-03 | — | — | US | disclosed |
| US-20150266867-A1 | MONOBACTAM ORGANIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | NOVARTIS AG (CH) | 2015-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266867-A1 | MONOBACTAM ORGANIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | MGAM, MGAM2, BPGM | CTSK 1729/4885CTSS 2061/4885CYP1A2 299/4885 |
| US-20190231752-A1 | MONOBACTAM ORGANIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | MGAM, MGAM2, BPGM | CTSK 1729/4885CTSS 2061/4885CYP1A2 299/4885 |
| US-20200276169-A1 | MONOBACTAM ORGANIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | MGAM, MGAM2, BPGM | CTSK 1729/4885CTSS 2061/4885CYP1A2 299/4885 |
| US-10369138-B2 | Monobactam organic compounds for the treatment of bacterial infections | MGAM, MGAM2, BPGM | CTSK 1729/4885CTSS 2061/4885CYP1A2 299/4885 |
| US-20160051523-A1 | MONOBACTAM ORGANIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | MGAM, MGAM2, BPGM | CTSK 1729/4885CTSS 2061/4885CYP1A2 299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.